Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Obstructive sleep apnoea ups risk of optic neuropathy

06 Sep 2018

Individuals with obstructive sleep apnoea (OSA) are at higher risk of developing optic neuropathy compared with those who do not have the condition, a study has found.

Researchers identified 5,129 individuals with OSA and 51,290 controls from the Taiwan Longitudinal Health Insurance Database. Mean age of the entire cohort was 48.2 years, and the majority (65.6 percent) were male. Compared with controls, OSA patients were more likely to have comorbid hypertension, diabetes, atherosclerosis, coronary artery disease, hyperlipidaemia and migraine (p<0.0001 for all).

Optic neuropathy occurred in 30 OSA patients vs 132 controls. Cox proportional hazard analysis revealed that OSA was associated with about a twofold higher risk of optic neuropathy (adjusted hazard ratio [HR], 1.95; 95 percent CI, 1.30–2.92). This association persisted regardless of the presence of comorbidity. The risk was especially higher in subgroups of patients aged <45 years (adjusted HR, 4.21; 1.93–9.18) and those who were male (adjusted HR, 1.93; 1.17–3.18).

Of note, treatment with continuous positive airway pressure (CPAP) showed no protective effect on the risk. The adjusted HRs for developing optic neuropathy vs controls were 2.31 (1.07–4.99) in the group of OSA patients who underwent CPAP and 1.82 (1.12–2.97) in the group who did not receive treatment.

In a separate cohort of 4,143 individuals with optic neuropathy and 41,430 controls, the ophthalmic condition was associated with an elevated risk of OSA (adjusted HR, 1.45; 1.02–2.07). The risk was particularly higher in subgroups of individuals aged 45–64 years (adjusted HR, 1.76; 1.08–2.86) and those who were male (adjusted HR, 1.55; 1.01–2.39).

Researchers postulated that mechanisms by which OSA may increase the risk of optic neuropathy may involve hypoxia, vascular dysregulation, and increased intracranial pressure and vasoactive substances (vascular endothelial growth factor and endothelin-1).

Additional studies with a larger sample size are needed to clarify the efficacy of treatment for OSA in reducing the risk of optic neuropathy, they added.

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).